Geovax Labs Inc (GOVX)

Geovax Labs Inc stock is traded at $0.158, with a volume of 1,451,601. It is down -5.95% in the last 24 hours and down -45.23% over the past month. Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.